



Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 20 December 2022.

I am pleased to confirm the following.

Question 1			
Does Milton Keynes University Hospital NHS Foundation Trust have any local treatment		Yes	
guidelines/pathways/protocols/algorithms for the treatment of non-small cell lung cancer?		We follow OUH protocol	

Question 2

Does Milton Keynes University Hospital NHS Foundation Trust have protocols for the use of the following targeted drug therapies in the treatment of non-small cell lung cancer?

5551111111111111		
Sotorasib (Lumykras)	Yes	No
	lf yes please see	
	que	estion 3
Entrectinib (Rozlytrek)	Yes	No
Larotrectinib (Vitrakvi)	Yes	No
Dabrafenib (Tafinlar)	Yes	No
Trametinib (Mekinist)	Yes	No
Capmatinib (Tabrecta)	Yes	No
Tepotinib (Tepmetko)	Yes	No
Bevacizumab (Avastin)	Yes	No
Ramucirumab (Cyramza)	Yes	No
Atezolizumab (Tecentriq)	Yes	No
Durvalumab (Imfinzi)	Yes	No
Cemiplimab- (Libtayo)	Yes	No
Nivolumab (Opdivo)	Yes	No
Pembrolizumab (Keytruda)	Yes	No
Ipilimumab (Yervoy)	Yes	No
Afatinib (Giotrif)	Yes	No
Dacomitinib (Vizimpro)	Yes	No
Erlotinib (Tarceva)	Yes	No
Gefitinib (Iressa)	Yes	No
Osimertinib (Tagrisso)	Yes	No
Amivantamab (Rybrevant)	Yes	No
Mobocertinib (Exkivity)	Yes	No
trastuzumab deruxtecan (Enhertu)	Yes	No
Alectinib (Alecensa)	Yes	No

As a teaching hospital, we conduct education and research to improve healthcare for our patients. During your visit students may be involved in your care, or you may be asked to participate in a clinical trial. Please speak to your doctor or nurse if you have any concerns.

Brigatinib (Alunbrig)	Yes	No
Ceritinib (Zykadia)	Yes	No
Crizotinib (Xalkori)	Yes	No
Lorlatinib (Lorviqua)	Yes	No
Entrectinib (Rozlytrek)	Yes	No
Pralsetinib (Gavreto)	Yes	No
Selpercatinib (Retsevmo)	Yes	No
Nintedanib (Vargatef®)	Yes	No

Question 3

If a local protocol for the use of Sotorasib (Lumykras) for the treatment of non-small cell lung cancer is available please could a copy be provided?

Question 4

Does Milton Keynes University Hospital NHS Foundation Trust	Yes	No
have any local pathways/protocols/guidelines for the use of molecular biomarker testing in diagnosis/treatment of non-small cell lung cancer?	lf yes p provide a	

Question 5

Is Milton Keynes University Hospital NHS Foundation Trust part of a Cancer alliance or network, if so which ones?

MKUH follow Oxford University Hospital protocols – we sit on E of E cancer Network.

Our tertiary centre is OUH and we clinically link to their protocols

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.